Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Pharmacokinet ; 34(1): 79-90, 1998 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-9474474

RESUMO

There is no doubt that the prognosis for systemic vasculitides has been considerably improved by the use of immunosuppressive agents, chiefly cyclophosphamide. Increasingly, we are becoming aware of the enormous burden of chronic 'grumbling' disease, the high incidence of relapse and the longer term effects of toxic therapy in these patients. The general approach is more intense therapy (with intermittent high dose 'pulses' or lower dose continuous cyclophosphamide) in the initial phase of therapy to induce remission, followed by a less toxic therapy in the maintenance phase (either longer intervals between pulses or a switch to a less toxic drug, such as azathioprine). The pathogenetic mechanisms in vasculitis, which are becoming more precisely defined, are diverse, but cyclophosphamide remains the drug of choice. A number of different cyclophosphamide regimens are in use, which reflects the current dilemma of trying to balance effectiveness with toxicity in diseases where the quality of long term survival remains unsatisfactory. Evidence from controlled trials does not support major differences in immediate outcome between different regimens of cyclophosphamide. Future studies need to address the use of agents designed to interfere precisely with the underlying pathogenetic mechanisms. Alternative approaches should also be considered, for example the use of sublethal doses of cyclophosphamide, with autologous bone marrow rescue, which may achieve long lasting remission or even cure.


Assuntos
Ciclofosfamida/uso terapêutico , Imunossupressores/uso terapêutico , Vasculite/tratamento farmacológico , Ensaios Clínicos Controlados como Assunto , Análise Custo-Benefício , Ciclofosfamida/administração & dosagem , Ciclofosfamida/farmacocinética , Intervalo Livre de Doença , Esquema de Medicação , Humanos , Imunossupressores/administração & dosagem , Imunossupressores/farmacocinética , Indução de Remissão , Vasculite/fisiopatologia
2.
Br J Clin Pract ; 48(6): 302-3, 1994.
Artigo em Inglês | MEDLINE | ID: mdl-7848791

RESUMO

A total of 6833 doses of medication were prescribed to 753 hospital inpatients in general wards over a 24-hour period (excluding medicines prescribed on an as-required basis and medicines prescribed for the first time during the 24-hour period). Of these, 574 (8.4%) doses were omitted, representing at least one omitted dose in 242 (32.1%) patients. Many of the omitted doses were of symptomatic treatments and in 43% of instances omission was deemed, retrospectively, to have been beneficial. Some omissions, however, were of a potentially life-threatening nature. The most common reasons for omission were that the patient refused the drug or that the nurse thought the drug unnecessary, the patient was on 'nil by mouth' or was too ill or unable to take the medicine. Thus, omission of prescribed medicines in general wards is common, often of little consequence or even beneficial, but of a potentially serious nature.


Assuntos
Tratamento Farmacológico/estatística & dados numéricos , Pacientes Internados/estatística & dados numéricos , Cooperação do Paciente , Hospitais de Distrito , Hospitais Gerais , Hospitais de Ensino , Humanos , Reino Unido
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...